New results from AlzeCure's pain project TrkA-NAM presented at the pain conference IASP 2024

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that its presentation about the preclinical project TrkA-NAM against osteoarthritis pain and other severe pain conditions, which is presented at the IASP 2024 World Congress on Pain on August 5-9, is now available in its entirety on the company's website.

The poster presentation, which is given by Dr. Märta Segerdahl, Chief Medical Officer at AlzeCure, describes the development of ACD137, the lead drug candidate in the TrkA-NAM program, which exhibits very good potency and selectivity for the target mechanism. The substance has shown powerful pain-relieving effects in several different preclinical models, including neuropathic and nociceptive pain, which indicates a wide range of use for these substances. ACD137 has previously also shown anti-inflammatory effects, which can further strengthen the pain-relieving properties.

The presentation, titled Pharmacological Effects of ACD137, a Potent and Selective Negative Allosteric Modulator of TrkA, was written by, among others, Pontus Forsell, project leader and Head of Discovery and Research at AlzeCure. The other authors include Gunnar Nordvall, Maria Backlund, Veronica Lidell, Azita Rasti, Cristina Parrado-Fernandez, Johan Sandin and Märta Segerdahl.

”NGF/TrkA signaling is a well-validated and promising alternative for novel analgesics without the side effects and addiction problems observed with opioids. Identification of selective and potent small molecule TrkA-NAM agents such as ACD137 could potentially avoid some of the side effects observed for anti-NGF antibodies due to a more selective mechanism of action, while maintaining the analgesic effect,” said Pontus Forsell, project leader and Head of Discovery and Research at AlzeCure.

”In our TrkA-NAM program, we have identified highly potent and selective TrkA-NAM substances, including ACD137, and demonstrated pain relief in preclinical models in vivo, both in neuropathic and nociceptive pain, with relevance for osteoarthritis-like pain, which indicates a broad potential for the mechanism of action. We are happy to see a strong and increased interest in this program among external players, e.g. as an alternative to opioids” said Martin Jönsson, CEO of AlzeCure Pharma AB.

The abstract and the poster are available on AlzeCure’s website (https://www.alzecurepharma.se/en/presentations-and-interviews/).